MedTrace Logo

Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy

NCT01290744 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-06-04

No results posted yet for this study

Summary

This study is a double-blind, randomized controlled trial examining the effect on ENL reactions of giving an additional year of clofazimine after completion of MDT in leprosy.

Conditions

  • Borderline Lepromatous Leprosy
  • Lepromatous Leprosy

Interventions

DRUG

Clofazimine

Clofazimine 100mg daily for 12 months after completion of MDT.

DRUG

Placebo

Daily for 12 months

Sponsors & Collaborators

  • Paul Saunderson

    lead OTHER

Principal Investigators

  • Marivic Balagon, MD · LWM

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01290744 on ClinicalTrials.gov